Patents by Inventor Jean DEFOURNY

Jean DEFOURNY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT
    Publication number: 20230405085
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gas-dermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdennin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AA V2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Application
    Filed: May 5, 2023
    Publication date: December 21, 2023
    Inventors: Christine PETIT, Paul AVAN, Sedigheh DELMAGHANI, Jean DEFOURNY, Asadollah AGHAIE, Saaid SAFIEDDINE, Alice EMPTOZ
  • Prevention and/or treatment of hearing loss or impairment
    Patent number: 11679140
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: June 20, 2023
    Assignees: INSTITUT PASTEUR, Centre National de la Recherche Scientifique (CNRS), Universite Clermont Auvergne, Sorbonne Universite
    Inventors: Christine Petit, Paul Avan, Sedigheh Delmaghani, Jean Defourny, Asadollah Aghaie, Saaid Safieddine, Alice Emptoz
  • PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT
    Publication number: 20200353039
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventors: Christine PETIT, Paul AVAN, Sedigheh DELMAGHANI, Jean DEFOURNY, Asadollah AGHAIE, Saaid SAFIEDDINE, Alice EMPTOZ
  • Prevention and/or treatment of hearing loss or impairment
    Patent number: 10751385
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 25, 2020
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Clermont Auvergne
    Inventors: Christine Petit, Paul Avan, Sedigheh Delmaghani, Jean Defourny, Asadollah Aghaie, Saaid Safieddine, Alice Emptoz
  • PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT
    Publication number: 20180055908
    Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.
    Type: Application
    Filed: February 19, 2016
    Publication date: March 1, 2018
    Inventors: Christine PETIT, Paul AVAN, Sedigheh DELMAGHANI, Jean DEFOURNY, Asadollah AGHAIE, Saaid SAFIEDDINE, Alice EMPTOZ